Show simple item record

dc.contributor.authorJelin, Elma
dc.contributor.authorWisløff, Torbjørn
dc.contributor.authorJørstad, Øystein Kalsnes
dc.contributor.authorHeiberg, Turid
dc.contributor.authorMoe, Morten Carstens
dc.date.accessioned2020-02-25T08:29:20Z
dc.date.available2020-02-25T08:29:20Z
dc.date.issued2019-10-03
dc.description.abstract<i>Objective</i> - To prospectively explore the following patient-reported outcome measures (PROMs) in the management of neovascular age-related macular degeneration (nAMD): (1) self-reported visual function, (2) symptom-state, (3) general-health and (4) satisfaction of treatment.<p> <p><i>Methods and analysis</i> - Corresponding to the four PROMs, participants responded to the following questionnaires: (1) National Eye Institute Visual-Functioning-Questionnaire (NEI-VFQ-25), (2) Patient-Acceptable-Symptom-Status (PASS 5), (3) EuroQol-Group-Questionnaire (EQ-5D-3L) and (4) Dimensions of Importance in Treatment of nAMD (DITAMD). Data were collected at baseline and after 3, 6 and 12 months of intravitreal antivascular endothelial growth factor treatment. Results were evaluated with t-tests and mixed linear regression analyses.<p> <p><i>Results</i> - The study included 197 patients. At baseline NEI-VFQ-25 (79.53±14.52) and EQ-5D (0.74±0.28) had relatively high scores, whereas PASS 5 was below ‘acceptable’ (3.30±0.80). At 12 months NEI-VFQ-25 and PASS 5 showed significant improvement, whereas EQ-5D and DITAMD remained unchanged. At baseline patients receiving treatment of the better-seeing eye (BSE) (n=52) reported significantly worse NEI-VFQ-25 and PASS 5 than patients for whom treatment only involved the worse-seeing eye (WSE), (n=145). In contrast to BSE patients, there was no improvement of NEI-VFQ-25 for WSE patients at 12 months, despite a significant improvement in best-corrected visual acuity (BCVA). Two independent variables, treatment including the BSE and BCVA for the treated eye, were found to predict both NEI-VFQ-25 and PASS 5.<p> <p><i>Conclusion</i> - After 12 months of nAMD treatment, there was a significant improvement in PASS 5 and NEI-VFQ-25, the latter depending on whether therapy included BSE. EQ-5D and DITAMD remained unaltered.en_US
dc.identifier.citationMoe, Wisløff, Heiberg, Jørstad. Patient-reported outcome measures in the management of neovascular age related macular degeneration: a 1-year prospective study . BMJ Open. 2019en_US
dc.identifier.cristinIDFRIDAID 1749783
dc.identifier.doi10.1136/bmjophth-2019-000353
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/10037/17471
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.journalBMJ Open
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2019 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801en_US
dc.titlePatient-reported outcome measures in the management of neovascular age related macular degeneration: a 1-year prospective studyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record